Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novartis AG ( NVS ) Saturday announced new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria or CSU, a chronic and debilitating form of hives.
ASTERIA I is the final pivotal registration study for omalizumab in CSU to be announced. Results of the study were presented Saturday for the first time at the 22nd Congress of the European Association of Dermatology and Venereology or EADV in Istanbul, Turkey.
http://www.nasdaq.com/article/novar...e-form-of-chronic-skin-disease-20131005-00013
ASTERIA I is the final pivotal registration study for omalizumab in CSU to be announced. Results of the study were presented Saturday for the first time at the 22nd Congress of the European Association of Dermatology and Venereology or EADV in Istanbul, Turkey.
http://www.nasdaq.com/article/novar...e-form-of-chronic-skin-disease-20131005-00013